Journal Article

Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18–24 Months: A phase Ⅳ clinical trial

Zheng, Yan, Pu, Yi, Jiang, Ruiju, Li, Yadong, Jiang, Ya, Pu, Jing, Dou, Youjian, Yang, Haitao, Xu, Min, Che, Yanchun, Yin, Qiongzhou, Deng, Yan, Cai, Wei, Zhao, Zhimei, Ying, Zhifang, Li, Jingyu, Yang, Jing, Bao, Wenmei, Lei, Jin, Shi, Li

2024

Overview

There has been no data on the immunogenicity and safety of the 4th booster dose of the sIPV immunization in 18–24 months old children in post-marketing studies of large cohort providing with robust results. In a phase Ⅳ randomized, double-blinded clinical trial, 1200 participants aged 2 months were immunized with three consecutive doses of sIPV at 2, 3, and 4 months old to complete primary immunization. Out of the 1200 participants, 1129 received the 4th dose of sIPV as booster immunization. Immunogenicity was evaluated in 1100 participants. Seropositive rates of the anti-poliovirus type 1, 2, and 3 neutralizing antibodies were 99.9 %, 98.0 %, 98.2 %, respectively, with GMTs of 557.0, 146.1, 362.0 one year after primary vaccination. After booster vaccination between 18 and 24 months old, the seropositive rates for 3 types all reached 100.0 %, with GMTs of 8343.6, 5039.6, 5492.0, respectively. Particularly for the anti-poliovirus type 2 antibody, the GMT was 230.4 after primary immunization, maintained to 146.1 one year after primary immunization, and increased to as high as 5039.6 after booster vaccination. The GMT ratios between each batch groups after booster immunization were between 0.67 and 1.50, meeting the immunological equivalence criteria. The incidence rate of adverse reaction was 23.0 %, which was comparable to those in the phase Ⅲ trial but had a lower incidence. Furthermore, no SUSAR was reported in this study. In conclusion, as the anti-poliovirus antibodies gradually waned one year post sIPV primary vaccination, especially the type 2 antibody waned to a very low level, suggesting the importance of the booster immunization for children at the age of 18–24 months old. The booster shot can greatly enhance the antibody level and protect children from the potential risk of infection with WPV and VDPV by supplementing the anti-poliovirus type 2 immunity gap in the current real world. Clinic Trial Registration. NCT04224519.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: adverse effects / Age / Allergy and Immunology / Antibodies / Antibodies, Viral / Booster immunization / Child / Child, Preschool / Children / China / Clinical trials / Consistency / Durability / Fever / Health risks / Humans / Immunization / Immunogenicity / Immunogenicity, Vaccine / Immunology / Inactivated poliovirus vaccine / Infant / Poliomyelitis / Poliomyelitis - prevention & control / Poliovirus / Poliovirus Vaccine, Inactivated - adverse effects / Poliovirus Vaccine, Oral / risk / Sabin strain / secondary immunization / seroprevalence / vaccination / Vaccines